CCEP
ACCE-researchedOverview
ACCE thesis
CCEP bottles, cans, and distributes Coca-Cola trademark products across Western Europe, Australia, and Indonesia - the operational grunt work that turns syrup concentrate into $17B+ in annual revenue. The franchise model locks in territory exclusivity and shifts brand-building costs to Atlanta, letting CCEP harvest margin on volume while Coca-Cola Company absorbs the advertising spend. The Indonesia and Pacific operations acquired through the 2021 Amatil merger remain the underpenetrated growth vector, with per-capita consumption in those markets running well below European levels. At 15.7x forward earnings with a 22.9% ROE, the market is pricing this as a low-growth toll booth - which is roughly accurate - but the 2025 price/mix cycle in Europe and ongoing cost efficiencies from the Amatil integration should push operating margins past current levels without requiring any volume heroics. This isn't a compounder that rewrites its own story; it's a cash-generative franchise with a clear capital return program that earns its place in a concentrated book only if you're buying the yield and the defensiveness, not a re-rating.
- highElevated leverage ratioDebt/Equity of 1.28 is meaningful for a consumer defensive; limits financial flexibility if revenue growth stalls near 0.2% YoY.
- moderateNear-zero revenue growthRevenue YoY growth of only +0.2% and QoQ decline of -4.1% suggest top-line momentum has stalled despite 5y CAGR of 6.5%.
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
Price
Valuation
INVESTORSix independent models converge on one confidence-weighted fair value, with full methodology and editable assumptions.
- +All six models: DCF, P/E and EV/EBITDA comps, Graham, dividend discount, residual income
- +Scenario bands, sensitivity tornado, and the 5-year historical valuation range
- +Editable DCF workbench with saved scenarios
Quality
INVESTORThe full quality picture: conviction breakdown, earnings quality, score history, and backtested returns.
- +Conviction score breakdown and earnings-quality grade
- +Growth / value / quality / momentum component scores
- +90-day score history and score-threshold backtests
Analysts
Wall Street consensus
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
- +Price-target low / average / high vs the current price, with implied upside
- +Forward revenue and EPS consensus by fiscal year
- +ACCE fair-value models lined up against the Street
Smart Money
PROFollow the institutions: 13F position changes, insider trades, and active 13D activist filings.
- +Quarter-over-quarter institutional position changes
- +Recent open-market insider transactions
- +Active 13D activist filings and top holders
Compare
Where it sits vs peers
Algorithmic peers (6)
| Ticker | Company | Mcap | P/E | ROE | D/E | Yield | Quality | |
|---|---|---|---|---|---|---|---|---|
| CCEP.L | Coca-Cola Europacific Partners PLC | $44.1B | 19.7 | 23.5% | 1.28 | 2.7% | - | Compare |
| KDP | Keurig Dr Pepper Inc. Common Stock | $42.1B | 31.3 | 5.1% | 0.63 | 2.9% | - | Compare |
| 9633.HK | Nongfu Spring Co., Ltd. | $55.3B | 23.4 | 50.0% | 0.11 | 0.0% | - | Compare |
| MNST | Monster Beverage Corporation | $87.6B | 41.4 | 25.7% | -0.25 | 0.0% | - | Compare |
| CCH.L | Coca-Cola HBC | $20.7B | 18.2 | 26.0% | 0.94 | 2.4% | - | Compare |
| VBL.NS | Varun Beverages Limited | $14.9B | 42.2 | 16.9% | 15.87 | 0.5% | - | Compare |
Sector report card
Where CCEP ranks against its sector peers on each metric.
News and Record
Press releases mentioning this company
Ask anything, Pro feature
Ask questions about this stock in plain language. Answered from company fundamentals + recent valuations.